<DOC>
	<DOCNO>NCT02884037</DOCNO>
	<brief_summary>In Non-alcoholic fatty ( NAFLD ) liver disease patient , investigator hypothesize rifaximin might act Gram-negative bacteria IBO thereby inhibit LPS-mediated proinflammatory cytokine production . This work evaluate efficacy 6 month administration rifaximin NAFLD patient .</brief_summary>
	<brief_title>Rifaximin Modify Pathogenesis Non-Alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description>The investigator aim study effect rifaximin NAFLD . 126 patient biopsy-proven NAFLD [ 42 steatosis , 84 non-alcoholic steatohepatitis ( NASH ) ] enrol open-label , prospective , multicentric cohort study . BMI , AST , ALT , gamma glutamyl transferase ( γ-GGT ) , lipid profile , homeostatic model assessment ( HOMA ) , serum endotoxin , Toll-like receptor 4 ( TlR4 ) , interleukin-6 ( IL-6 ) , IL-10 , tumor necrosis factor-α ( TNF-α ) cytokeratin-18 ( CK-18 ) level measure 6 month administration rifaximin ( 1100-1200 mg/day ) .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>woman men age 1870 year , biopsy proven NAFLD /or NASH without mild moderate fibrosis ( fibrosis stage 03 ) , persistently abnormal ALT 2 occasion , participant provide write informed consent prior screen treatment antibiotic 3 month begin study , allergy rifamycin rifaximin , presence type liver disease pancreatic biliary tract disease , excessive alcohol intake ( &gt; 20 g/day ) , pregnant lactate woman , hypothyroidism , systemic inflammatory condition ( e.g . connective tissue diseases inflammatory bowel disease ) , bariatric surgery blind loop , evidence hepatic decompensation ( ascites , hepatic encephalopathy , varix ) , history myocardial infarction and/ stroke within 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NAFLD</keyword>
	<keyword>Rifaximin</keyword>
	<keyword>Endotoxin Homeostatic Model Assessment</keyword>
</DOC>